Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic LeukemiaAndrew W. Roberts, John F. Seymour, Matthew S. Davids et al.|New England Journal of Medicine|2015Cited by 1.9k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic LeukemiaRichard R. Furman, Susan O’Brien, Michael Hallek et al.|New England Journal of Medicine|2014Cited by 1.7k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic LeukemiaJohn C. Byrd, Richard R. Furman, Bonnie K. Harrington et al.|New England Journal of Medicine|2015Cited by 890
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S. Davids, John F. Gerecitano, Andrew W. Roberts et al.|Journal of Clinical Oncology|2017Cited by 752
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cellsBrian G. Till, Oliver W. Press, Michael C. Jensen et al.|Blood|2008Cited by 719